An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
Dr. Reddy’s Laboratories announced that its Board of Directors will meet on May 9, 2025, to review and approve the audited financial results for the quarter and fiscal year ending March 31, 2025, and to consider recommending a final dividend for the financial year 2024-25. In compliance with SEBI regulations, the company has also announced the closure of its trading window from March 25, 2025, to May 11, 2025, to prevent insider trading during this period, which may impact investor activities.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients, and proprietary products, with a market focus on providing affordable and innovative medicines globally.
YTD Price Performance: -14.23%
Average Trading Volume: 1,849,068
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $11.25B
See more insights into RDY stock on TipRanks’ Stock Analysis page.